文献速递产科母胎医学

阿司匹林对糖尿病妊娠胎儿生长的影响:按White分类分析

Impact of aspirin on fetal growth in diabetic pregnancies according to White classification.
PubMed 文献 · Am J Obstet Gynecol · 2017-06-30

该研究对母婴医学单位高危阿司匹林试验中444例孕前糖尿病孕妇进行二次分析,按White分类分为血管病变组(53例)和非血管病变组(391例)。阿司匹林组整体出生体重Z评分较高(0.283,95%CI 0.023-0.544,P=0.03),但调整后仅非血管病变组关联显著(0.341,95%CI 0.677-0.006,P=0.044),血管病变组呈相反但非显著趋势(-0.416,95%CI -1.335至0.503,P=0.6)。非血管病变组阿司匹林组大于胎龄儿发生率高于安慰剂组(40.2% vs 26.6%,P=0.005),小于胎龄儿发生率两组均为8%。

要点

  • 阿司匹林未降低整体或任一组小于胎龄儿发生率(两组均8%)。
  • 非血管病变糖尿病孕妇用阿司匹林后大于胎龄儿发生率高于安慰剂组(40.2% vs 26.6%,P=0.005)。
  • 阿司匹林与非血管病变组出生体重Z评分较高相关(0.341,95%CI 0.677-0.006,P=0.044)。

核心结论

  • 与假设不一致,阿司匹林未降低整体队列或任一组的小于胎龄儿发生率。
  • 阿司匹林治疗的糖尿病妊娠中大于胎龄儿发生率增加,鉴于巨大儿相关的母婴发病率增加,这一发现值得关注。

研究设计与样本

  • 对母婴医学单位高危阿司匹林试验中糖尿病孕妇队列进行二次分析。
  • 共纳入444例孕前糖尿病且结局数据完整的孕妇,其中血管病变组53例,非血管病变组391例。
  • 按White分类分为非血管病变组(White B、C、D级)和血管病变组(White R、F、RF级)。
  • 出生体重转换为按分娩时孕周和新生儿性别标准化的Z评分。
  • 采用两样本t检验比较阿司匹林与安慰剂组出生体重Z评分差异,线性回归模型估计血管组、随机分组及交互作用对标准化出生体重百分位的影响,协变量包括体重指数、吸烟、种族和产次。

主要发现

  • 整体队列中阿司匹林与较高的出生体重Z评分显著相关(0.283;95%CI 0.023-0.544;P=0.03)。
  • 调整模型中,阿司匹林与较高出生体重Z评分的关联仅限于非血管病变糖尿病孕妇的新生儿(0.341;95%CI 0.677-0.006;P=0.044)。
  • 血管病变糖尿病孕妇的新生儿中观察到相反但非显著效应(-0.416;95%CI -1.335至0.503;P=0.6)。
  • 阿司匹林与出生体重Z评分的关系按血管组不同,差异显著(P=0.046)。
  • 非血管病变糖尿病中阿司匹林随机组大于胎龄儿出生多于安慰剂组(40.2% vs 26.6%;P=0.005)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Current US Preventive Services Task Force and other guidelines recommend low-dose aspirin for all pregnant women with pregestational diabetes mellitus to prevent preeclampsia and small-for-gestational-age birth. The Maternal-Fetal Medicine Units High-Risk Aspirin trial did not show a reduction in either preeclampsia or small-for-gestational-age birth in diabetic women. OBJECTIVE: Our objective was to reassess the impact of aspirin on fetal growth in diabetic pregnancies overall and according to White classification. We hypothesized that aspirin improves fetal growth in pregnancies with vascular complications of diabetes at highest risk for poor fetal growth. STUDY DESIGN: We conducted secondary analysis of the cohort of diabetic women enrolled in the Maternal-Fetal Medicine Units High-Risk Aspirin trial. The impact of aspirin prophylaxis on birthweight was assessed in the overall cohort and in 2 groups categorized according to White classification as nonvascular (White class B, C, D) or vascular (White class R, F, RF). Birthweight was converted to Z-score normalized for gestational age at delivery and neonatal sex. Difference in birthweight Z-score between aspirin and placebo was tested with a 2-sample t test. The effect of vascular group, aspirin vs placebo randomization, and the interaction of the 2 on normalized birthweight percentile was estimated with linear regression with a multivariable model including covariates body mass index, tobacco use, race, and parity. The percentage of small and large-for-gestational-age newborns born to aspirin- vs placebo-treated women was compared between groups using Pearson exact χ2 analysis, and an adjusted model was estimated by logistic regression. RESULTS: All 444 women with pregestational diabetes and complete outcome data were included (53 vascular, 391 nonvascular). Aspirin was significantly associated with a higher birthweight Z-score (0.283; 95% confidence interval, 0.023-0.544) in the overall cohort (P = .03). In the adjusted model, the association of aspirin with higher birthweight Z-score was confined to neonates of women with nonvascular diabetes (0.341; 95% confidence interval, 0.677-0.006; P = .044). An opposite but nonsignificant effect was observed among neonates from women with vascular diabetes (-0.416; 95% confidence interval, -1.335 to 0.503; P = .6). This difference in the relationship of aspirin and birthweight Z-score by vascular group was significant at P = .046. Aspirin-randomized women with nonvascular diabetes had more large-for-gestational-age births than those treated with placebo (40.2 vs 26.6%; P = .005). Small-for-gestational-age births occurred at the same frequency with aspirin vs placebo randomization in the overall cohort (8% in each group) and in each vascular group. CONCLUSION: Inconsistent with our hypothesis, aspirin did not reduce small-for-gestational-age births in the overall cohort or either group. The increased incidence of large-for-gestational-age infants in aspirin-treated diabetic gestations is of potential concern given the known increased maternal and neonatal morbidity associated with macrosomia.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Adkins K, Allshouse AA, Metz TD, et al. Impact of aspirin on fetal growth in diabetic pregnancies according to White classification. Am J Obstet Gynecol. 2017. PMID: 28599894. doi:10.1016/j.ajog.2017.05.062

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。